Could These Huge Health-Care Buyouts Continue?

By David Williamson | More Articles
January 20, 2012 | Comments (1)

The following video is part of our "Motley Fool Conversations" series in which technology editor/analyst Andrew Tonner and health-care editor/analyst David Williamson discuss topics across the investing world.

In this video, Andrew and David sit down to talk about the continuing acquisitions Big Pharma is making to acquire next gen hepatitis-C treatments. They go over the most recent deal, Bristol-Myers Squibb's $2.5 billion purchase of Inhibitex, compare it to Gilead's purchase of Pharmasset, and discuss which company would be next at the altar if buyout mania keeps going.

Biotech investors are always looking for the next runaway success. Motley Fool co-founder David Gardner has recently identified a small-cap health-care company that he believes is poised for monster returns. To find out which stock is about to reap huge profits from fundamentally changing its industry download our exclusive special free report "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited time offer and your opportunity to discover this game changing company before the market does by. Click here to access your report -- it's totally free.

The Steve Jobs Betrayal
You may already know that in the final year of his life, Jobs revealed a stunning betrayal — and told his biographer, "I will spend my last dying breath... and every penny of Apple's $40 billion in the bank to right this wrong." What was it that made Jobs so irate — and why could it make a few in-the-know investors some major profits over the coming months and years?

Enter your email address below to find out what made Jobs so enraged!

David Williamson and Andrew Tonner have no positions in the stocks mentioned above. The Motley Fool owns shares of Gilead Sciences. Motley Fool newsletter services recommend Gilead Sciences and Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.

Report this Comment On January 23, 2012, at 8:02 AM, sdturbo wrote:

In my sincere opinion people are doused by the
brokers, analysts,news makers misguided and
ripped apart in the day light, just to fill their own
fat balley. Please be advised that there won't be
another take over of ACHN or IDIX until some proven
results. BMY is smart and they made a deal with
INHX conditional, if it failed in FDA approval the deal will be scraped with little or no penalty of 216 millon.
Sell ACHN and IDIX at these prices or make put
or short it for long run. There is no deal talk in
process.

Add your comment.

Compare Brokers

Fool Disclosure

DocumentId: 1762137, ~/Articles/ArticleHandler.aspx, 5/27/2012 2:18:18 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
	DOW	12,454.83	-74.92	-0.60%
	S&P 500	1,317.82	-2.86	-0.22%
	NASD	2,837.53	-1.85	-0.07%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes